TNF and melanoma: To further verify the mechanism of RdB/IL23/p35-mediated therapeutic benefit in vivo, IFN-γ and/or TNF-α depletion experiments were performed by injecting B16-F10 melanoma-bearing mice with anti-IFN-γ and/or anti-TNF-α antibodies.